European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

COVID-19-Outbreak Response combining E-health, Serolomics, Modelling, Artificial Intelligence and Implementation Research

Descripción del proyecto

Una respuesta integrada contra la COVID-19

Al igual que ante cualquier pandemia, las medidas de respuesta y contención contra la COVID-19 deben basarse en una combinación de información clínica, epidemiológia e inmunológica. En el proyecto CORESMA, financiado con fondos europeos, se trabaja en un sistema de vigilancia sanitaria para móviles destinado a obtener datos clínicos al instante y mejorar la evaluación del riesgo en los países con más probabilidades de verse fuertemente afectados por la COVID-19. Los investigadores del proyecto estudiarán asimismo el papel de la inmunidad cruzada o parcial preexistente contra la COVID-19 en la susceptibilidad. Mediante modelización exhaustiva e inteligencia artificial, identificarán variables predictoras de consecuencias graves, las dinámicas de transmisión y la eficacia de las intervenciones. Los resultados no solo ayudarán a hacer frente a la pandemia, sino también a ofrecer una estrategia sostenible de cara al futuro.

Objetivo

Among the biggest challenges in the COVID-19 outbreak are the lack of triangulation of clinical, epidemiologic and immunological information for evidence- based response strategies.
Our overriding ambition is to overcome this deficit through field studies and implementation research in specific populations early enough to already serve in the response to the current outbreak. Four technical work packages (WP) address the four main objectives:
To provide real-time clinical data to improve risk assessment and response, deploying an established mHealth Surveillance Outbreak Response Management and Analysis System (SORMAS) in Nepal, Ivory Coast, Ghana and Nigeria; countries likely to be affected more intensively than the EU.(WP I)
To implement differential serolomics (multiplex serology) for population serum samples from Germany and Nepal for investigating pre-existing cross or partial immunity against COVID-19 and impact on susceptibility.(WP II)
To apply comprehensive modeling, sampling and artificial intelligence on data from the first two work packages in order to assess predictors for severe outcome, transmission dynamics and intervention effectiveness.(WP III)
To measure and improve quality of epidemic containment measures through implementation research in countries particularly vulnerable to the COVID-19 epidemic, in order to tailor effective and efficient control measures to health systems realities in Nepal and Ivory Coast, and to reduce the intensity of importation into the EU. (WP IV)
We combine a) an accelerated ad-hoc outbreak response to address the urgency and b) a sustainable strategy to serve beyond the current public health threat from COVID-19. Software maturity, established networks, pre-approval investments and interdisciplinary expertise among partners - including first hand from China - shall generate first findings within weeks, such as validated criteria for high-risk groups, effectiveness of contact tracing, set-up serolomics platform.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Aportación neta de la UEn
€ 1 108 205,00
Dirección
INHOFFENSTRASSE 7
38124 Braunschweig
Alemania

Ver en el mapa

Región
Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 1 108 205,00

Participantes (6)